Preceding infections, immune factors, and outcome in Guillain-Barré syndrome

Neurology

Volumn 56, Issue 6, 2001, Pages 758-765

  Hadden, R D M ^a,c,f   Karch, H ^c   Hartung, H P ^c,d   Zielasek, J ^c   Weissbrich, B ^c   Schubert, J ^c   Weishaupt, A ^c   Cornblath, D R ^e   Swan, A V ^b   Hughes, R A C ^a   Toyka, K V ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF GRAZ   (Austria)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CYTOKINE RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR; SELECTIN; TUMOR NECROSIS FACTOR RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; CAMPYLOBACTER JEJUNI; CLINICAL FEATURE; CYTOMEGALIC INCLUSION BODY DISEASE; DEATH; DIARRHEA; DISEASE CLASSIFICATION; EPSTEIN BARR VIRUS; GUILLAIN BARRE SYNDROME; HUMAN; INFECTION; LYMPHOCYTE MIGRATION; MAJOR CLINICAL STUDY; NEUROPATHY; PARESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; T LYMPHOCYTE ACTIVATION; WALKING;

EID: 0035957291     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.56.6.758     Document Type: Article

References (43)

1. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome
2. Electrophysiological classification of Guillain-Barré syndrome: Clinical associations and outcome
3. Campylobacter jejuni infection and Guillain-Barré syndrome
4. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome
5. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies
6. A prospective study of acute idiopathic neuropathy: II. Antecedent events
7. The spectrum of antecedent infections in Guillain-Barré syndrome. A case control study
8. Cytomegalovirus infection and Guillain-Barré syndrome: The clinical, electrophysiologic, and prognostic features
9. Immunopathogenesis and treatment of the Guillain-Barré syndrome: Part I
10. Six widespread bacterial clones among Escherichia coli K1 isolates
11. The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders
12. Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection
13. The use of semi-automated EBV IgG avidity determination for the diagnosis of infectious mononucleosis
14. Electrodiagnostic criteria for polyneuropathy and demyelination: Application in 135 patients with Guillain-Barré syndrome
15. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome
16. Campylobacter jejuni infection and Guillain-Barré syndrome: A case-control study
17. Serologic evidence of previous Campylobacter jejuni infection in patients with the Guillain-Barré syndrome
18. Antibodies to gangliosides and galactocerebroside in patients with Guillain-Barré syndrome with preceding Campylobacter jejuni and other identified infections
19. Autoantibodies to GM1b and GalNAc-GD1a: Relationship to Campylobacter jejuni infection and acute motor axonal neuropathy in China
20. Close association of IgA anti-ganglioside antibodies with antecedent Campylobacter jejuni infection in Guillain-Barré and Fisher's syndromes
21. 1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection
22. Campylobacter jejuni lipopolysaccharides in Guillain-Barré syndrome: Molecular mimicry and host susceptibility
23. Reactivity of serum IgG anti-GM1 ganglioside antibodies with the lipopolysaccharide fractions of Campylobacter jejuni isolates from patients with Guillain-Barré syndrome (GBS)
24. Role of infection in Guillain-Barré syndrome: Laboratory confirmation of herpes viruses in 41 cases
25. Clinical and serological studies in a series of 45 patients with Guillain-Barré syndrome
26. Antiganglioside antibodies in Guillain-Barré syndrome after a recent cytomegalovirus infection
27. Cytomegalovirus infections and anti-GM2 antibodies in Guillain-Barré syndrome
28. Acute cytomegalovirus infection and IgM anti-GM2 antibody
29. Circulating adhesion molecules and inflammatory mediators in demyelination: A review
30. Mechanisms of immune regulation in the peripheral nervous system
31. Circulating tumor necrosis factor-α correlates with electrodiagnostic abnormalities in Guillain-Barré syndrome
32. Guillain-Barré syndrome without sensory loss (acute motor neuropathy): A subgroup with specific clinical, electrodiagnostic and laboratory features
33. The distribution of ganglioside-like moieties in peripheral nerves
34. Age and Guillain-Barré syndrome severity
35. A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value
36. Plasmapheresis and Guillain-Barré syndrome: Analysis of prognostic factors and the effect of plasmapheresis
37. The prognosis and main prognostic indicators of Guillain-Barré syndrome. A multicentre prospective study of 297 patients
38. Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange
39. Reasons for persistent disability in Guillain-Barré syndrome
40. Fatal Guillain-Barré syndrome
41. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome
42. Two patterns of clinical recovery in Guillain-Barré syndrome with IgG anti-GM1 antibody
43. Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside